ClinConnect ClinConnect Logo
Search / Trial NCT04441814

FOUND - Ancillary Study to Smile Protocol NCT03654105

Launched by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO · Jun 18, 2020

Trial Information

Current as of July 09, 2025

Enrolling by invitation

Keywords

Covid Lung Cancer Screening Subsolid Pulmonary Nodules Low Dose Ct Screening Blood Biomarkers

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Elegibility to annual LDCT screening
  • Absence of tumors for at least 5 years
  • Signed informed consent form meet inclusion criteria outlined in SMILE Protocol NCT03654105
  • Exclusion Criteria:
  • Hypersensitivity to acetylsalicylic acid, salicylates or any of the excipients
  • Chronic treatment with acetylsalicylic acid, or other anti-clotting or anti-coagulant drugs
  • Treatment with methotrexate
  • Existing Mastocytosis
  • History of asthma induced by the administration of salicylates or substances to similar activity, particularly non-steroidal anti-inflammatory drugs
  • Gastroduodenal ulcer
  • Hemorrhagic diathesis
  • Severe chronic pathology
  • Serious psychiatric problems
  • Previous treatment with Cytisine
  • Abuse of alcohol or other substances

About Fondazione Irccs Istituto Nazionale Dei Tumori, Milano

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano is a leading cancer research and treatment institution in Italy, dedicated to advancing the understanding and management of oncological diseases. As a prominent clinical trial sponsor, the foundation focuses on innovative research aimed at developing new therapeutic strategies and improving patient outcomes. With a commitment to translational medicine, it collaborates with a network of national and international partners to facilitate cutting-edge clinical trials, enhance cancer care, and contribute to the global body of oncological knowledge.

Locations

Milan, , Italy

Patients applied

0 patients applied

Trial Officials

Ugo Pastorino, MD

Principal Investigator

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials